Antares Pharma, Inc., a pharmaceutical company, focuses on self-injection pharmaceutical products and technologies, and topical gel-based products. It offers injection devices, which include Zomajet 2 Vision, Zomajet Vision X, Twin-Jector EZ II, and Tjet for human growth hormone; Medi-Jector Vision for insulin; Vibex disposable pressure assisted auto injectors that enables a controlled pressure delivery of drugs into the body utilizing a spring power source; and disposable pen injectors, which are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. The company also provides Anturol, an oxybutynin ATD (advanced transdermal delivery)gel, which is in Phase III clinical trials for the treatment of overactive bladder; Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; LibiGel, a transdermal testosterone gel that is in Phase III clinical studies for the treatment of female sexual dysfunction; and Nestorone contraceptive formulation products, which has completed Phase II clinical trials. Antares Pharma, Inc. markets its products to pharmaceutical companies primarily in the United States and Europe. It has collaborative arrangements and license agreements with Teva Pharmaceutical Industries, Ltd.; Ferring Pharmaceuticals BV; JCR Pharmaceuticals Co., Ltd.; BioSante Pharmaceuticals, Inc.; Jazz Pharmaceuticals; and Population Council. The company was founded in 1979 and is based in Ewing, New Jersey.

Acquired Companies: ENDOS Pharma